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Background
Electroconvulsive therapy (ECT) is considered to be the most
effective treatment in severe major depression. The identifica-
tion of reliable predictors of ECT response could contribute to a
more targeted patient selection and consequently increased ECT
response rates.
Aims
To investigate the predictive value of age, depression severity,
psychotic and melancholic features for ECT response and
remission in major depression.
Method
A meta-analysis was conducted according to the PRISMA
statement. A literature search identified recent studies that
reported on at least one of the potential predictors.
Results
Of the 2193 articles screened, 34 have been included for meta-
analysis. Presence of psychotic features is a predictor of ECT
remission (odds ratio (OR) = 1.47, P = 0.001) and response (OR =
1.69, P < 0.001), as is older age (standardised mean difference
(SMD) = 0.26 for remission and 0.35 for response (P < 0.001)). The
severity of depression predicts response (SMD = 0.19, P = 0.001),
but not remission. Data on melancholic symptoms were
inconclusive.
Conclusions
ECT is particularly effective in patients with depression with
psychotic features and in elderly people with depression. More
research on both biological and clinical predictors is needed to
further evaluate the position of ECT in treatment protocols for
major depression.
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There is no consensus on the position of electroconvulsive therapy
(ECT) in current depression treatment protocols. For depression
with psychotic features, ECT is the first-line treatment according to
several guidelines,1–3 whereas others recommend antidepressant
monotherapy4 or in combination5with antipsychotics. In clinical prac-
tice ECT is often used to treat patients with treatment-resistant depres-
sion. In a recent meta-analysis the response rate was 58% for patients
with treatment-resistance depression and 70% for those without.6
Despite many studies on possible predictors of response to ECT,
Kellner et al7 recently concluded that no useful clinical predictors
have emerged. A possible explanation for this apparent lack of clinical
predictors is the fact that many studies investigating predictors are
underpowered to find an effect. Furthermore, heterogeneity between
studies may mask the ability of a clinical variable to predict ECT
response. Since many relatively small studies have been performed,
meta-analysis may be useful to calculate effect sizes of possible predic-
tors. A more accurate prediction of response and remission would be
helpful to guide decision-making and preferably treat those patients
likely to respond to ECT. This could substantially shorten depres-
sive-episode duration.8 To our knowledge, there have been no meta-
analyses that look at prediction of response and remission separately.
The difference between the two is, however, clinically relevant.
Remission has become the gold standard for depression treatment,
because patients who do not remit have a poorer prognosis than
those who do. They have a greater chance of relapse and recurrence.9
Method
Age, depression severity, psychotic and melancholic features were
selected as potential predictors in this meta-analysis. They were
selected because of their possible clinical relevance and because
their role in the prediction of response and remission of depression
after ECT is unclear. In an earlier meta-analysis,6 older age and
psychotic features were weakly associated with greater ECT
response rates, but heterogeneity was notable. Analyses of
symptom severity and melancholic features were inconclusive as a
result of study heterogeneity in the same analysis.
This meta-analysis was conducted and reported according to
the PRISMA-P (preferred reporting items for systematic review
and meta-analysis protocols) and MOOSE guidelines10,11 (supple-
mentary Table 1; available at http://dx.doi.org/10.1192/bjp.2017.
28). Objectives and eligibility criteria were specified in advance
and documented in a protocol (available from the authors on
request).
Eligibility criteria
In order to obtain details of recent original studies on the predictive
effect of age, severity of depression, melancholic and psychotic
symptoms on the effectiveness of ECT (as it is currently practised)
in patients with depression we applied the following eligibility
criteria:
(a) studies assessing the effect of brief- or ultrabrief-pulse ECT on
depression severity, published in or after 1995, articles are
written in English;
(b) adults (>18 years of age) diagnosed with uni- or bipolar depres-
sion as confirmed by Research Diagnostic Criteria , DSM-III-R,
DSM-IV, DSM-IV-TR, DSM-5 or ICD-10 criteria;
(c) presence of psychotic or melancholic symptoms as confirmed
by a structured diagnostic or clinical interview;
(d) classification of patients as ‘responder/non-responder’ or
‘remitter/non-remitter’ based on scores on valid clinician-
rated depression scales (Hamilton Rating Scale for Depression
(HRSD) or Montgomery–Åsberg Depression Rating Scale
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(MADRS)) that were administered before and soon after the
end of the ECT course;
(e) effect sizes (or raw data enabling calculation of the effect size) of
single-response predictors were provided or could be obtained
by contacting the authors.
Data sources and study selection
We searched Embase, Medline, Web of Science, Cochrane, PubMed
publisher and Google scholar up to 17 February 2017. Articles pub-
lished before 1995 were discarded. We chose to select studies from
1995 onward to get an overview of predictors of ECT as it is cur-
rently practised. The indication for, and practice of ECT has
changed substantially over the years. This implies that including
older studies means increased heterogeneity.
Combinations of the words depression, electroconvulsive
therapy, response, remission and the four predictors (age, depres-
sion severity, psychotic and melancholic symptoms) were used.
References from reviews and relevant articles were searched for add-
itional studies. The titles and abstracts were screened for relevance.
We selected articles in English. Searches were combined and dupli-
cates removed. To maintain statistical independence of effect sizes,
studies that reported on the same population were identified. When
redundancy was obvious, the most comprehensive report with the
largest sample size was used.
The inclusion of papers in the meta-analysis was evaluated sep-
arately by two independent researchers, the first (L.v.D.) and second
author (S.v.d.A.). Disagreements were resolved via consensus. If no
agreement was obtained, there was further discussion with two
senior researchers (T.B. and D.S.).
Data-collection process
When reported results were insufficiently detailed but the remain-
ing inclusion criteria were fulfilled, corresponding authors were
contacted for clarification and re-contacted if necessary. Authors
were contacted if an email address was available and the author
had published in the past 10 years. If data on only response or remis-
sion were available, authors were contacted to ask if data on the
other outcome measure could also be provided. In total, 62
authors were contacted, 21 of the responding authors provided us
with the data necessary to use their study in the meta-analysis.12–32
Data extraction
The information was independently extracted from each article by
two investigators (L.v.D. and S.v.d.A.) using a data extraction
sheet with the following data:
(a) study characteristics: year, country and design of the study,
diagnostic classification and depression severity scale used;
(b) characteristics of the study sample: number of participants, per-
centage female participants, percentage of patients with psych-
otic symptoms, mean age of the participants, average episode
duration and percentage with medication resistance;
(c) ECT related: the average number of ECT sessions, electrode
position used;
(d) outcome measure: general response and remission rates,
response and remission rates for patients with depression
with and without psychotic symptoms, for patients with and
without melancholic symptoms, average age (and s.d.) and
depression severity score (and s.d.) for ‘responders/non-
responders’ and ‘remitters/non-remitters’.
Quality assessment
There was a strict use of eligibility criteria to select studies for the
meta-analysis. Diagnostic criteria had to be used and an objective
measurement of response based on one of the clinician-rated
depression scales was required.
Furthermore, two of the reviewers (L.v.D. and T.B.) independ-
ently assessed several other quality aspects of the included studies
based on the GRADE method33 and the Newcastle–Ottawa
Quality Assessment Scale34 for cohort studies. The following three
quality criteria were assessed:
(a) design of the study (pro- or retrospective);
(b) observational or interventional study;
(c) completeness of outcome data (more v. less than 20%
drop-out).
Outcome measures
The primary outcome was remission, the secondary outcome was
response. The use of continuous data would be a more sensitive
method to detect differences. However, we chose to use remission
as primary outcome measure because it is often used as such in clin-
ical practice. Remission is associated with a lower full symptomatic
recurrence rate compared with achieving treatment response.9,35 In
all the selected studies, response was defined as a reduction of at
least 50% from the baseline HRSD or MADRS score. Remission
was usually defined as a depression scale score equal to or below
7 (for HRSD-17) or 10 (for HRSD-21, HRSD-24 and MADRS).
Statistical analyses
The predictors were analysed separately with Comprehensive Meta-
Analysis (CMA version 3). The effect size was analysed as an odds
ratio (OR) for the dichotomous variables psychotic and melancholic
symptoms. For age and severity of depression, the effect size was
represented by the standardised mean difference (SMD). For each
predictor, a random-effects model was computed since we expect
the true effect to vary from study to study dependent on the com-
position of the study population.36 The Stata ‘metan’ package was
used for part of the analyses on publication bias.
Without consideration of the study weights in the random-
effects model, we calculated the average age of all ‘responders/
non-responders’ and ‘remitters/non-remitters’. In the same way,
response and remission percentages were calculated for those with
and without psychotic and melancholic symptoms.
Publication bias
When there were ten or more studies in an analysis,37 funnel plots
were used to visualise whether or not the effects found were depend-
ent on the sample size.36 Publication bias was formally assessed with
the Egger’s test in CMA for age and depression severity given their
continuous outcome38 and with the Harbord’s test in Stata for the
dichotomous predictors.39
Heterogeneity and sensitivity analysis
Heterogeneity was assessed using Cochran’s Q-test and I2 statistics.
An I2 statistic of 0–40% was interpreted as heterogeneity that might
not be important, 30–60% may represent moderate heterogeneity,
50–90% may represent substantial heterogeneity and 75–100% is
considerable heterogeneity.37
Heterogeneity was further explored conducting sensitivity ana-
lyses. Therefore, we calculated the effect using fixed-effect and
random-effects modelling and evaluated the effect of the modelling
procedure on the overall effect per predictor. A substantial differ-
ence in the effect calculated by the fixed- and random-effects
model will be seen only if studies are markedly heterogeneous.40
Furthermore, we compared the overall effects based on potential
clinical sources of heterogeneity such as the continent of origin
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(according to World Health Organization classification), the study
population (average age and episode duration of the sample, the
percentage of patients with psychotic features, percentage with
medication resistance) and treatment parameters (length of ECT
course and electrode position used). The effects were also compared
based on the before mentioned study quality criteria.
Results
Selection of studies
After removal of duplicates and studies published before 1995
(Fig. 1), the literature search yielded 2193 potentially relevant arti-
cles. We excluded 1991 articles after review of titles and abstracts.
The full texts of the 202 remaining studies were analysed; 171 of
them did not meet eligibility criteria and were excluded, 2 articles
were added through reference lists and 1 through cross-reference.
In total, 34 articles were selected and used in this meta-ana-
lysis.12–32,41–53 The interrater reliability was good, with an interrater
agreement of 96.1% (kappa (κ) = 0.87, 95% CI 0.78–0.96).
Study characteristics
Overall, the selected studies reported on 3276 participants that
received an ECT course (supplementary Table 2). More than half
of the studies (52.9%) were carried out in Europe. A total of 25
studies included psychotic symptoms, 28 had data on age, 28 on
depression severity and 7 on melancholic symptoms.
Studies had between 15 and 414 participants (on average 99 per
study). The majority of the participants (64.3%) were women (range
27.0–77.8%) and 32.6% had psychotic symptoms (range 6.7–
70.6%). Patients were on average 57.1 years of age (range of mean
age was 33.1–74.8). Three studies reported on the same large
sample, but on a different predictor.19,31,54 The data of the largest
sample were used for the above calculations of study characteristics.
One of the three was eventually excluded54 because data on
psychotic symptoms were provided by the authors of the largest
sample.19
Results of the quality assessment can be found in the supple-
mentary material (supplementary Table 3). There were 7 retrospect-
ive studies and 27 had a prospective design. In total, 26 studies were
observational, 8 of them were interventional. Eight studies had a
drop-out rate of more than 20%.
Psychotic symptoms
Remission
Data on the presence of psychotic symptoms and remission
following ECT were provided in 21 studies. For remission, the
OR under the random-effects model was 1.47 (95% CI 1.16–1.85,
P = 0.001, I2 = 36.6) (Fig. 2(a)). The remission rate for patients
with depression and psychotic symptoms was 57.8%; for those
without psychotic symptoms it was 50.9%.
Response
Data on the presence of psychotic symptoms and response to ECT
were provided in 21 studies. Psychotic features were positively asso-
ciated with a higher ECT response rate under the random-effects
model (Fig. 2(b)). The OR was 1.69 (95% CI 1.27–2.24, P < 0.001,
I2 = 25.8). The response rate for patients with depression and psych-
otic symptoms was 78.9% and for those without psychotic symp-
toms it was 70.6%.
4244 Records identified through database searching
2115 Embase
935 Medline ovid
753 Web of science
241 Cochrane
200 Google scholar
4042 Excluded based on review of title and abstract
1537 Duplicates removed
514 Published before 1995
1991 Excluded after initial screening of titles
and abstracts
202 articles screened
2 articles added through
reference list
1 extra article added
through cross-reference
171 excluded after review of full text
14 No full text available/only congress abstract
34 Reported on the same population
19 Not only patients with depression
34 No diagnostic classification or depression scale
66 Outcome or predictor not useable
4 No use of brief or ultrabrief-pulse ECT
34 studies included in
meta analysis
Fig. 1 Study selection.
ECT, electroconvulsive therapy.
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Age
Remission
In total, 24 papers provided data on age and remission. Age was
positively associated with higher ECT remission rates under the
random-effects model (Fig. 2(c)). The SMD was 0.26 (95% CI
0.13–0.38, P < 0.001, I2 = 53.4). The average age of those whose con-
dition remitted was 59.7 years, compared with 55.4 years for those
whose condition did not.
Response
Data on age and response to ECT could be extracted from 25 papers.
Age was positively associated with a higher ECT response under the
random-effects model (Fig. 2(d)). The SMD was 0.35 (95% CI 0.23–
0.47, P < 0.001, I2 = 29.7). The average age of those who responded
was 58.2 years, compared with 54.9 years for those who did not
respond.
Melancholic symptoms
Remission
There were seven studies that provided data on presence of melan-
cholic symptoms and remission after ECT. The OR under the
random-effects model was 1.24 (95% CI 0.69–2.22, I2 = 63.9,
Fig. 2(e)). The difference was, however, not significant (P = 0.467).
The remission rate for patients with depression and melancholic
symptoms was 62.9%, for those without melancholic symptoms it
was 65.5%.
Response
Data on melancholic symptoms and response could be obtained
from five studies. The OR under the random-effects model was
1.71 (95% CI 0.43–6.84, I2 = 85.9, Fig. 2(f)). The difference was,
however, not significant (P = 0.452) and there was considerable het-
erogeneity. The response rate for patients with depression and
Psychotic symptoms 
(a) (b)
Age
(c) (d)
Study name Statistics for each study
Odds
ratio
Lower
limit
Upper
limit P
Odds ratio and 95% CI
0.01 0.1 1 10 100
No psychotic
symptoms
Psychotic
symptoms
Study name Statistics for each study
Odds
ratio
Lower
limit
Upper
limit P
Odds ratio and 95% CI
0.01 0.1 1 10 100
No psychotic
symptoms
Psychotic
symptoms
Study name Statistics for each study
Std diff
in means
Lower
limit
Upper
limit P
Std diff in means and 95% CI
–1.00 –0.50 0.00 0.50 1.00
Favours younger Favours older
Study name Statistics for each study
Std diff
in means
Lower
limit
Upper
limit P
Std diff in means and 95% CI
–1.00 –0.50 0.00 0.50 1.00
Favours younger Favours older
Alves et al (2016)30 1.029 0.297 3.573 0.964
Birkenhager et al (2003)15 3.667 1.163 11.563 0.027
Birkenhager et al (2010)14 0.945 0.426 2.094 0.889
Bjolseth et al (2015)16 4.538 1.411 14.596 0.011
Dombrovski et al (2005)43 1.288 0.791 2.099 0.309
Huuhka et al (2007)32 0.962 0.455 2.036 0.920
Kellner et al (2016)29 1.637 0.689 3.886 0.264
Kho et al (2005)44 2.517 0.913 6.940 0.075
Loo et al (2011)46 4.296 0.978 18.869 0.054
Medda et al (2014)47 0.520 0.282 0.958 0.036
Oudega et al (2014)20 2.488 1.002 6.176 0.049
O´Connor et al (2001)19 1.468 0.924 2.334 0.104
Piccinni et al (2009)49 0.222 0.029 1.709 0.148
Rhebergen et al (2015)22 2.447 1.084 5.521 0.031
Spashett et al (2015)26 1.337 0.872 2.050 0.184
Semkovska et al (2016)24 1.466 0.645 3.334 0.361
Sobin et al (1996)51 0.963 0.408 2.270 0.931
Spaans et al (2013)25 1.849 0.772 4.428 0.168
Tokutsu et al (2013)52 2.405 0.602 9.603 0.214
Van Waarde et al (2013)27 1.653 0.662 4.129 0.282
Winkler et al (2014)28 5.185 0.179 150.542 0.338
1.468 1.163 1.853 0.001
Alves et al (2016)30 0.988 0.222 4.407 0.987
Bharadwaj et al (2012)13 7.414 0.331 165.985 0.207
Birkenhager et al (2003)15 8.469 1.676 42.799 0.010
Birkenhager et al (2010)14 2.547 0.986 6.575 0.053
Bjolseth et al (2015)16 1.486 0.462 4.781 0.506
Dannon & Grunhaus (2001)41 0.333 0.039 2.871 0.317
De Vreede et al (2005)42 0.471 0.154 1.443 0.187
Huuhka et al (2007)32 2.094 0.864 5.075 0.102
Kellner et al (2016)29 2.769 0.924 8.292 0.069
Loo et al (2011)46 5.896 0.696 49.923 0.104
Medda et al (2014)47 0.801 0.430 1.494 0.486
O´Connor et al (2001)19 2.478 0.927 6.624 0.070
Okazaki et al (2010)48 1.905 0.321 11.309 0.478
Oudega et al (2014)20 1.329 0.481 3.672 0.584
Rhebergen et al (2015)22 1.621 0.724 3.630 0.240
Semkovska et al (2016)24 1.670 0.712 3.920 0.239
Spaans et al (2013)25 0.935 0.381 2.294 0.883
Spashett et al (2014)26 2.523 1.405 4.530 0.002
Tokutsu et al (2013)52 7.472 0.390 143.234 0.182
Tominaga et al (2011)53 1.433 0.185 11.120 0.731
Van Waarde et al (2013)27 2.752 0.909 8.328 0.073
1.688 1.274 2.237 <0.001
Alves et al (2016)30 –0.038 –0.644 0.568 0.901
Bauer (2009)12 0.242 –0.314 0.798 0.393
Birkenhager et al (2003)15 0.475 –0.077 1.026 0.091
Birkenhager et al (2010)14 0.021 –0.374 0.416 0.916
Bjolseth et al (2015)16 –0.024 –0.485 0.437 0.920
Bumb et al (2015)17 0.250 –0.635 1.134 0.580
Dombrovski et al (2005)43 0.292 0.073 0.511 0.009
Huuhka et al (2007)32 0.078 –0.293 0.448 0.681
Joshi et al (2015)18 0.854 0.093 1.615 0.028
Kellner et al (2016)29 0.245 –0.017 0.506 0.066
Lin et al (2015)45 –0.087 –0.507 0.332 0.683
Loo et al (2011)46 0.354 –0.121 0.829 0.144
Medda et al (2014)47 –0.087 –0.372 0.199 0.552
O´Connor et al (2001)19 0.266 –0.024 0.556 0.073
Oudega et al (2014)20 0.089 –0.347 0.526 0.688
Piccinni et al (2009)49 0.259 –0.675 1.192 0.587
Rhebergen et al (2015)22 0.552 0.186 0.917 0.003
Semkovska et al (2016)24 0.715 0.369 1.061 0.000
Spaans et al (2013)25 0.850 0.407 1.293 0.000
Spashett et al (2014)26 0.539 0.341 0.736 0.000
Schoeyen et al (2015)23 0.780 –0.107 1.668 0.085
Tokutsu et al (2013)52 –0.571 –1.191 0.048 0.071
Van Waarde et al (2013)27 0.150 –0.278 0.578 0.493
Winkler et al (2014)28 –0.247 –1.283 0.790 0.641
0.258 0.132 0.383 <0.001
Alves et al (2016)30 0.272 –0.540 1.084 0.511
Bauer et al (2009)12 0.265 –0.427 0.956 0.453
Bharadwaj et al (2012)13 –1.601 –3.072 –0.130 0.033
Birkenhager et al (2003)15 0.714 0.093 1.336 0.024
Birkenhager et al (2010)14 0.181 –0.257 0.620 0.417
Bjolseth et al (2015)16 0.020 –0.463 0.504 0.934
Bumb et al (2015)17 0.315 –0.785 1.415 0.574
Huuhka et al (2007)32 0.330 –0.086 0.745 0.120
Joshi et al (2015)18 0.881 0.083 1.680 0.031
Kellner et al (2016)29 0.185 –0.093 0.462 0.192
Ozkan Kuscu et al (2015)21 0.247 –0.544 1.038 0.540
Lin et al (2015)45 –0.104 –0.651 0.443 0.710
Loo et al (2011)46 0.018 –0.447 0.482 0.941
Medda et al (2014)47 0.187 –0.120 0.494 0.232
O´Connor et al (2001)19 0.440 0.077 0.803 0.017
Okazaki et al (2010)48 0.119 –0.762 0.999 0.792
Oudega et al (2014)20 0.464 –0.038 0.966 0.070
Rhebergen et al (2015)22 0.552 0.186 0.917 0.003
Schoeyen et al (2015)23 0.452 –0.488 1.392 0.346
Semkovska et al (2016)24 0.729 0.382 1.075 0.000
Spaans et al (2013)25 0.845 0.382 1.308 0.000
Spashett et al (2014)26 0.546 0.314 0.778 0.000
Tokutsu et al (2013)52 –0.118 –0.982 0.747 0.790
Tominaga et al (2011)53 0.425 –0.533 1.383 0.384
VanWaarde et al (2014)27 0.269 –0.195 0.733 0.256
0.348 0.229 0.467 <0.001
Fig. 2 Random-effects meta-analyses.
Effect of psychotic symptoms on remission (a) and response (b) and age on remission (c) and response (d) of depression after electroconvulsive therapy (ECT). Random-effectsmeta-
analyses of the effect of melancholic symptoms on remission (e) and response (f) and depression severity on remission (g) and response (h) of depression after ECT. Std diff,
standardised difference.
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melancholic symptoms was 71.1% and for those without melan-
cholic symptoms it was 64.7%.
Depression severity
Remission
Data on depression severity and remission could be extracted from
23 studies. Remission following ECT was less likely in patients with
higher depression severity scores, although the effect was not
significant under the random-effects model (SMD =−0.10, 95%
CI −0.20–0.002, P = 0.054, I2 = 29.7, Fig. 2(g)).
Response
In total, 26 studies reported on depression severity and response to
ECT. A small but significant association was found between
response and baseline symptom severity scores on the HRSD or
MADRS, under the random-effects model (SMD 0.19, 95% CI
0.07–0.31, P = 0.001, I2 = 28.1, Fig. 2(h)). Patients with higher
scores were more likely to respond to ECT.
Publication bias
The funnel plots that could be generated revealed no obvious asym-
metry (see supplementary Fig 1). Given the limited number of
studies in the melancholia analyses, no funnel plots were generated
for this predictor. According to Egger’s and Harbord’s test there was
also no significant publication bias in all of these analyses (Table 1).
Heterogeneity and sensitivity analysis
A group of observational studies often shows considerable hetero-
geneity, regardless of the number of included studies. The
Cochran’s Q-test and I2 statistics were used to quantify heterogen-
eity. There was evidence of moderate heterogeneity in all of the ana-
lyses that were done (Table 2), and substantial heterogeneity in the
analyses on melancholic symptoms.
Heterogeneity was further explored conducting sensitivity ana-
lysis. Therefore, we calculated the effect using both fixed-effect and
random-effects modelling and evaluated the effect of the modelling
procedure on the overall effect per predictor. The difference
Melancholic symptoms 
(e) (f)
Depression severity
(g) (h)
Study name Statistics for each study
Odds
ratio
Lower
limit
Upper
limit P
Odds
ratio
Lower
limit
Upper
limit P
Odds ratio and 95% CI
0.01 0.1 1 10 100
no melancholic
symptoms
melancholic
symptoms
Study name Statistics for each study Odds ratio and 95% CI
0.01 0.1 1 10 10
no melancholic
symptoms
melancholic
symptoms
Study name Statistics for each study
Std diff
in means
Lower
limit
Upper
limit P
Std diff in means and 95% CI
–1.00 –0.50 0.00 0.50 1.0
Favours mild Favours severe
Study name Statistics for each study
Std diff
in means
Lower
limit
Upper
limit P
Std diff in means and 95% CI
–1.00 –0.50 0.00 0.50 1.00
Favours mild Favours severe
Alves et al (2016)30 0.852 0.203 3.588 0.828
Birkenhager et al (2010)14 32.206 4.135 250.857 0.001
Bjolseth et al (2015)16 1.686 0.146 19.470 0.676
Dombrovski et al (2005)43 1.448 0.826 2.539 0.196
Fink et al (2007)31 0.665 0.358 1.235 0.197
Kellner et al (2016)29 0.728 0.426 1.246 0.247
Loo et al (2011)46 1.556 0.582 4.155 0.378
1.241 0.694 2.217 0.467
Alves et al (2016)30 2.307 0.464 11.468 0.307
Birkenhager et al (2010)14 22.820 6.933 75.114 0.000
Bjolseth et al (2015)16 0.255 0.013 5.136 0.372
Kellner et al (2016)29 0.795 0.448 1.410 0.433
Loo et al (2011)46 0.684 0.261 1.790 0.439
1.705 0.425 6.840 0.452
Alves et al (2016)30 –0.279 –0.888 0.330 0.369
Bauer et al (2009)12 0.309 –0.249 0.866 0.278
Birkenhager et al (2003)15 –0.023 –0.567 0.521 0.933
Birkenhager et al (2010)14 –0.199 –0.604 0.207 0.336
Bjolseth et al (2015)16 –0.134 –0.595 0.327 0.569
Bumb et al (2015)17 –0.823 –1.740 0.094 0.079
Huuhka (2007)32 –0.155 –0.526 0.216 0.413
Joshi et al (2015)18 0.255 –0.477 0.986 0.495
Kellner (2016)29 –0.129 –0.389 0.132 0.333
Lin (2015)45 –0.221 –0.642 0.199 0.302
Loo et al (2011)46 –0.509 –0.988 –0.031 0.037
Medda et al (2014)47 0.106 –0.179 0.392 0.465
O´Connor et al (2001)19 –0.189 –0.479 0.101 0.201
Oudega et al (2014)20 –0.167 –0.604 0.270 0.454
Piccinni et al (2009)49 –0.697 –1.654 0.260 0.154
Rhebergen et al (2015)22 0.395 0.033 0.758 0.033
Schoeyen et al (2015)23 0.065 –0.794 0.923 0.883
Semkovska et al (2016)24 –0.079 –0.415 0.257 0.646
Spaans et al (2013)25 –0.509 –0.941 –0.077 0.021
Spashett et al (2014)26 0.000 –0.194 0.194 1.000
Tokutsu et al (2013)52 –0.486 –1.103 0.130 0.122
Van Waarde et al (2013)27 0.012 –0.416 0.439 0.958
Winkler et al (2014)28 0.434 –0.610 1.479 0.415
–0.097 –0.197 0.002 0.054
Alves et al (2016)30 0.441 –0.374 1.256 0.289
Bauer et al (2009)12 0.607 –0.093 1.306 0.089
Bharawadaj et al (2012)13 0.491 –0.939 1.920 0.501
Birkenhager et al (2003)15 0.397 –0.215 1.008 0.203
Birkenhager et al (2010)14 0.612 0.166 1.059 0.007
Bjolseth et al (2015)16 0.156 –0.328 0.640 0.527
Bumb et al (2015)17 –0.169 –1.266 0.928 0.763
Huuhka (2007)32 0.422 0.004 0.839 0.048
Joshi et al (2015)18 0.259 –0.510 1.027 0.509
Kellner et al (2016)29 0.068 –0.209 0.345 0.630
Ozkan Kuscu et al (2015)21 0.111 –0.680 0.901 0.784
Lin et al (2015)45 0.479 –0.072 1.029 0.088
Loo et al (2011)46 –0.045 –0.509 0.420 0.851
Medda et al (2014)47 0.345 0.037 0.653 0.028
O´Connor et al (2001)19 –0.066 –0.428 0.295 0.720
Okazaki et al (2010)48 0.277 –0.607 1.161 0.539
Oudega et al (2014)20 0.129 –0.368 0.627 0.610
Rhebergen et al (2015)22 –0.249 –0.610 0.111 0.175
Schoeyen et al (2015)23 –0.009 –0.939 0.922 0.986
Semkovska et al (2016)24 0.169 –0.167 0.506 0.324
Sivaprakash et al (2000)50 0.169 –0.575 0.913 0.656
Spashett et al (2014)26 0.489 0.257 0.720 0.000
Spaans et al (2013)25 –0.294 –0.742 0.154 0.198
Tokutsu et al (2013)52 0.370 –0.498 1.237 0.404
Tominaga et al (2011)53 –0.888 –1.879 0.103 0.079
Van Waarde et al (2013)27 0.269 –0.195 0.734 0.256
0.190 0.074 0.306 0.001
Fig. 2 Continued.
Table 1 Results of tests for publication bias
Intercept 95% CI P
Harbord’s test
Psychosis – remission 0.563 −0.289 to 1.415 0.182
Psychosis – response 0.011 −0.529 to 0.550 0.968
Melancholia – remission 1.739 −1.112 to 4.590 0.178
Melancholia – response 0.630 −4.641 to 5.900 0.729
Egger’s test
Age – remission −0.626 −2.164 to 0.912 0.408
Age – response −0.787 −1.960 to 0.386 0.178
Severity – remission −0.546 −2.014 to 0.922 0.447
Severity – response −0.350 −1.517 to 0.817 0.542
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between results of fixed- and random-effects analyses were small
(Table 2), confirming that heterogeneity in our analyses was limited.
Besides that, we compared the overall effects based on the
potential clinical sources of heterogeneity and study quality criteria
(as discussed). Continuous variables were analysed with meta-
regression, categorical variables were subjected to mixed-effects
subgroup analysis. Studies were excluded from the analyses if data
on the variable was not available. This can explain differences
found in overall effects.
Psychotic symptoms
Age and medication resistance were clinical sources of heterogeneity
in the remission analysis (Table 3). The predictive effect of psychotic
symptoms was stronger in samples with older patients and those with
lower levels of medication resistance. The results were not signifi-
cantly influenced by the other potential clinical sources of heterogen-
eity (length of the ECT course, episode duration, electrode position
and location of the study, supplementary Table 4).
The study quality criteria had no significant influence on the
results of the remission analysis (design of the study, drop-out
and whether or not it was an observational study, supplementary
Table 4). The length of the ECT course was a clinical source of het-
erogeneity in the response analysis. It was significantly related to the
effect size, with longer courses corresponding to a greater predictive
effect of psychotic symptoms on ECT response (Table 3). The
results were not significantly influenced by the other potential clin-
ical sources of heterogeneity (age, episode duration, therapy resist-
ance, electrode position, location of the study) or the study quality
criteria (design of the study, drop-out and whether or not it was
an observational study, supplementary Table 4).
Age
The most important clinical source of heterogeneity in the analyses
on the effect of age on response and remission after ECT, was the
average episode duration (Table 3). SMDs were greater in studies
with longer episode duration. Moreover, the predictive effect of
age was significantly higher in studies that used right unilateral or
variable electrode positions, compared with those only using bilat-
eral ECT in the remission analysis (Fig. 3a).
In the remission analysis, the SMD was also influenced by
whether it was an observational study, or an interventional study.
Interventional studies found on average higher SMDs than observa-
tional studies (Fig. 3b). The results were not influenced by the other
potential clinical sources of heterogeneity (psychotic symptoms,
medication resistance, length of the ECT course, location of the
study), or the other study quality criteria (design of the study and
drop-out, supplementary Table 4).
In the response analysis, the results were not significantly influ-
enced by the other potential clinical sources of heterogeneity
(psychotic symptoms, electrode position, location of the study,
medication resistance, length of the ECT course), or the study
quality criteria (design of the study, drop-out and whether or not
it was an observational study, supplementary Table 4).
Melancholic symptoms
Because of low patient numbers in part of the analyses and different
definitions of the concept of melancholia, results of the response
and remission analyses were considered to be inconclusive.
Therefore, sensitivity analyses were not performed.
Depression severity
In the remission analysis, there was no significant influence of the
potential clinical sources of heterogeneity (age, psychotic
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symptoms, episode duration, medication resistance, length of the
ECT course, location of the study). Drop-out was a source of hetero-
geneity in the remission analysis (Fig. 3c). Studies with drop-out
rates above 20% found that lower depression scale scores favoured
remission after ECT. Those with limited drop-out found no effect
at all of depression severity. There was no significant effect of the
other study quality criteria (design of the study and whether or
not it was an observational study, supplementary Table 4).
The results of the response analysis were not significantly influ-
enced by any of the potential clinical sources of heterogeneity (age,
electrode position, length of ECT course, episode duration, therapy
resistance, location of the study). The SMD in the response analysis
was influenced by the design of the study. Retrospective studies
found remarkably higher SMDs than prospective studies (Fig. 3d).
The results were not influenced by the other study quality criteria
(drop-out and whether or not it was an observational study, supple-
mentary Table 4).
Discussion
Main findings
This meta-analysis provides evidence for the superior efficacy of
ECT in patients with depression with psychotic features, in older
patients and in those with a more severe depression, whereas data
on melancholic symptoms were inconclusive. This is an important
finding, because identification of reliable predictors could contrib-
ute to more targeted patient selection, consequently increased
ECT response and remission rates and limited episode duration.
We included 34 studies reporting on 3276 patients with a
depressive disorder treated with ECT. There were relatively strict
inclusion criteria to select only high-quality studies and, in contrast
to previous meta-analyses on prediction of ECT efficacy, we made a
distinction between data on response v. remission.
Presence of psychotic symptoms had an OR of 1.69 (P < 0.001)
for response and 1.47 (P = 0.001) for remission. The SMD for older
age was 0.35 (P < 0.001) in the response analysis, for remission it
was 0.26 (P < 0.001). These are all rather small effect sizes.55
When we look at the average age of patients whose condition remit-
ted (59.7) and compare this with the age of those who did not remit
(55.4), the difference is only 4.3 years. One could hypothesise that
the age of 57 somehow resembles a turning point in remission fol-
lowing ECT. However, it is clear that not every person older than 57
will experience remission after treatment with ECT, just as remis-
sion will not occur in every patient with depression with psychotic
symptoms. Therefore, age and psychotic symptoms are no water-
proof predictors of ECT efficacy. They can, however, serve as one
of several factors that can guide treatment decision-making.
A weaker association was detected between the severity of
depression and response to treatment (SMD 0.19, P = 0.001).
Depression severity was not associated with remission. This
appears logical, since higher scores pre-ECT need a larger decrease
than lower scores to attain remission.
Psychomotor disturbance is a key marker not only of melancho-
lia but also of psychotic depression.56 Thus, those with depression
with psychotic features often have melancholic symptoms.
Consequently, the finding that depression with psychotic features
is a predictor of ECT response and remission indirectly points to
Table 3 Tests of heterogeneity – results of meta- regression
Beta 95% CI Q P
Psychosis
Response, length course 0.089 0.001 to 0.176 3.89 0.05*
Remission, age 0.040 0.006 to 0.073 5.32 0.02*
Remission, medication resistance −0.019 −0.036 to −0.003 5.20 0.02*
Age
Response, episode duration 0.037 0.005 to 0.068 5.30 0.02*
Remission, episode duration 0.044 0.016 to 0.073 9.15 <0.01**
* P < 0.05, **P < 0.01.
Age 
Severity 
Group by
Electrode position Statistics for each study Std diff in means and 95% CI
Std diff
in means
Lower
limit
Upper
limit P
Std diff
in means
Lower
limit
Upper
limit P
Std diff
in means
Lower
limit
Upper
limit P
Std diff
in means
Lower
limit
Upper
limit P
0.6650.187–0.1190.034BL
0.0080.7070.1050.406RUL
<0.0010.5190.1660.343VAR
–1.00 –0.50 0.00 0.50 1.00
Favours younger Favours older Favours younger Favours older
Group by
Observational Statistics for each study Std diff in means and 95% CI
0.0000.7850.2460.515No
0.0050.3120.0540.183Yes
–1.00 –0.50 0.00 0.50 1.00
Group by
Drop out Statistics for each study Std diff in means and 95% CI
0.6390.091–0.148–0.029No
0.003–0.075–0.364–0.220Yes
–1.00 –0.50 0.00 0.50 1.00
Favours mild Favours severe Favours mild Favours severe
Group by
Design Statistics for each study Std diff in means and 95% CI
0.0460.2270.0020.114Pro
Retro 0.496 0.308 0.685 <0.001
–1.00 –0.50 0.00 0.50 1.00
(a) (b)
(c) (d)
Fig. 3 Significant results of subgroup analyses.
Mixed-effects analysis of electrode position in the remission analysis of the predictor age (a), of the study quality criterion observational/interventional in the remission analysis of
the predictor age (b), of dropout in the remission analysis of the predictor severity (c) and of study design in the response analysis of the predictor severity (d). BL, bilateral; RUL, right
unilateral; VAR, variable; Pro, Prospective; Retro, Retrospective; Std diff, standardised difference.
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melancholic symptoms also having predictive potential. However,
this does not result from our analysis. The few studies that reported
onmelancholic symptoms did not use the same definition of melan-
cholia. Furthermore, one of the studies had a very low number of
patients without melancholic features,16 and another one had very
low numbers of individuals who responded/remitted in patients
without melancholic symptoms.14 This resulted in very large confi-
dence intervals and considerable heterogeneity. We conclude that
this predictor is insufficiently investigated to draw solid conclusions
on its predictive effect.
Several relevant factors have emerged from the heterogeneity
analysis. Presence of psychotic symptoms was a stronger predictor
of remission in older patients and in patients with limited medica-
tion resistance. Psychotic symptoms were a stronger predictor of
response for those with a longer ECT course. A stronger predictive
effect of psychotic symptoms in patients receiving a longer ECT
course could mean that patients with depression with psychotic
symptoms might benefit from longer ECT courses.
A limited episode duration is known to predict a good response
to ECT.6 However, in studies with longer episode duration, the pre-
dictive effect of age on response and remission was stronger. This is
remarkable, since we have no reason to expect that episode duration
per se has an influence on the strength of the predictive effect of age.
The value of the predictor age was also considerably higher in
studies that used right unilateral or variable electrode positions in
the remission analysis. As we look further, this result might be
mediated by the location at which the study was performed. Age
was a strong predictor of response and remission in studies
carried out in the USA and Europe, and although the difference
was not significant, the predictive effect was not that clear in
studies carried out in Asia. An explanation could be that studies
from Asia all use the standard bilateral electrode position, adminis-
ter relatively short ECT courses and participants had a lower
average age. The question therefore remains if the predictors that
show a significant effect are relevant independent of the already
known predictors and other confounders.
Besides the four predictors we investigated, there are several
other potential clinical predictors that have been subject to previous
meta-analyses. The predictive effect of the number of episodes, the
age of onset, gender and a bipolar diagnosis on the efficacy of ECT
appears to be non-existent.6 The lack of predictive value of a bipolar
diagnosis was confirmed by a second meta-analysis.57 There was a
significant influence of episode duration (SMD −0.43, P < 0.001;
I2 = 35%) on ECT response. The weighted mean episode duration
for those who responded was 6.6 months and 14 months for
those who did not respond. Medication failure was the second sig-
nificant predictor (OR 0.57, P = 0.002; I2 = 35%) for poorer ECT
response, as mentioned in the introduction. This result was also
confirmed by a second meta-analysis.58
Data on known response predictors (episode duration and
medication failure) and the percentage of patients with psychotic
symptoms were not always provided and could therefore not
always be accounted for in the current analyses. The results of the
heterogeneity analyses therefore have to be interpreted with care.
The effect size of psychotic symptoms as predictor of response
and remission was considerably higher than the effect found in a
recent meta-analysis on ECT response prediction by Haq et al (OR
= 1.34, P = 0.12).6 The same holds true for age (SMD 0.112, P =
0.25) and depression severity (SMD −0.022, P = 0.90). Differences
between the meta-analyses were that, in our study response and
remission rates were separated and strictly defined by HRSD or
MADRS score. In addition, we retrieved unpublished data from 21
authors, contributing to a more complete analysis of those studies.
To recapitulate, our study probably analysed a more homogeneous
sample that facilitated detection of significant differences.
Strengths
There are several strengths to this comprehensive meta-analysis. To
make sure we based our analysis on reliable data, we used relatively
strict criteria for selection of studies (use of a diagnostic instrument
and a validated clinician-rated depression scale). The second
strength is the separate analysis for response and remission. This
distinction enabled us to confirm the findings of one outcome cri-
terion by a second one. Our findings lead to the conclusion that
age and psychotic symptoms are stronger predictors of response
than of remission. The fact that we contacted a number of
authors for extra data contributed to a large sample to study and
a more complete data analysis of studies concerned, limiting publi-
cation bias. Furthermore, it enabled us to find sources of
heterogeneity.
Limitations
There are several limitations to our meta-analysis. Where strict
selection criteria can be considered a strength, they can also be con-
sidered a limitation. As a consequence, a number of (often large)
studies have been excluded. An example is a large Swedish study
(n = 990)59 that has only used Clinical Global Impression –
Improvement scores and not a clinician-rated depression scale
(HRSD or MADRS) to distinguish between individuals who
responded and those that did not. The results of this study are,
however, in line with our findings – a higher proportion of older
patients responded (84.3%) as compared with younger ones
(74.2%, P < 0.001) and patients with severe, depression with
psychotic features had the highest response rate (88.9%) compared
with patients with severe, non-psychotic depression (81.5%) and
patients with mild/moderate depression (72.8%, P < 0.001).
Furthermore, several seemingly suitable studies60,61 could not be
used because they have not reported on the value of predictors for
responders v. non-responders and could not provide us with these
data.
As mentioned before, we did not only use data from studies that
were designed specifically to look at the predictive effect of psychotic
symptoms or one of the other predictors. Part of the data could be
abstracted from studies with a different objective. Considering pub-
lication bias, this is an advantage. On the other hand, this is an extra
source of heterogeneity between the studies. Different populations
were studied, the studies had divergent designs, several depression
scales and versions of these scales were used and the definition of
remission can therefore not be exactly the same in every study.
Moreover, ECT practice and patient selection for ECT differs all
around the world.62 We tried to minimise the impact of this hetero-
geneity by including some of these parameters in heterogeneity ana-
lysis to determine their effect on outcome.
Despite the fact that more effective forms of ECT exist,63 we
have chosen not to exclude studies that use ultrabrief-pulse ECT.
Given its cognitive advantages it can be the preferred treatment
for a subgroup of patients with depression. The predictor results
of the studies that use only ultrabrief-pulse ECT29,46 are in line
with the overall results of our meta-analysis.
Clinical implications
Besides episode duration and treatment resistance, which are estab-
lished predictors for the efficacy of ECT, age, depression severity
and the presence of psychotic symptoms can also be of value in
the ECT treatment decision-making process. Previous studies
found a favourable response to ECT in patients with a short
episode duration and limited treatment resistance. When episode
duration is longer, age might be able to guide decision-making.
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ECT could be suggested relatively early to those prone to
respond or remit, thereby limiting depression duration and prevent-
ing a chronic trajectory of depressive symptoms. Other treatment
options can first be considered for those with lower response and
remission chances.
Research implications
We have used the general definition of melancholia in our meta-
analysis. Another strategy could be to investigate psychomotor dis-
turbance as measured by the CORE Assessment of Psychomotor
Functioning or the score on HRSD retardation and agitation item
scores as a more specific marker.64 Observable psychomotor dis-
turbance has been suggested as an essential criterion in making a
diagnosis of melancholia65 and proved to be a predictor of ECT
response in previous studies.66,67 For future projects, it could be
valuable to incorporate measurement of the severity of psycho-
motor disturbance next to the general definition of melancholia
so that the predictive effect of the presence of melancholia and
more specific psychomotor disturbance can be evaluated.
Our analysis examined a lot of (often) small studies that report
on two or three of the factors that are known to be relevant. Larger
studies that report on all of the identified predictors (and the pres-
ence of personality disorder68) could be valuable to get a clearer view
on the combined effect of several predictors.
A combination of these clinical variables with their biological
underpinnings could further improve response and remission pre-
diction and could serve as more objective tools to guide patient
treatment matching.
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